Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 6th, 2025
Amphastar Pharmaceuticals (NASDAQ: AMPH) said it will release results for its third quarter of 2025, which ended September 30, 2025, after market close on Thursday, November 6, 2025. The company will hold a conference call that day at 2:00 p.m. Pacific Time to discuss results, accessible by toll-free dial-in and via webcast on the company Investors page, with a replay posted within 24 hours.
The release reiterates forward-looking statements about product sales, development, regulatory timing, manufacturing capacity expansion, and other future events, and points readers to Amphastar's SEC filings for risk factors and additional details.
Amphastar Pharmaceuticals (NASDAQ: AMPH) ha detto che renderà noti i risultati del suo terzo trimestre 2025, terminato il 30 settembre 2025, dopo la chiusura del mercato di giovedì 6 novembre 2025. L'azienda terrà una conference call quel giorno alle 14:00 ora del Pacifico per discutere i risultati, accessibile tramite chiamata senza costi e via webcast sulla pagina Investitori dell'azienda, con una replica pubblicata entro 24 ore.
Il comunicato richiama dichiarazioni previsionali su vendite di prodotti, sviluppo, tempistiche regolatorie, espansione della capacità di produzione e altri eventi futuri, e invita i lettori a consultare i documenti SEC di Amphastar per i fattori di rischio e ulteriori dettagli.
Amphastar Pharmaceuticals (NASDAQ: AMPH) anunció que publicará los resultados de su tercer trimestre de 2025, que concluyó el 30 de septiembre de 2025, después del cierre del mercado el jueves 6 de noviembre de 2025. La compañía realizará una conferencia telefónica ese día a las 14:00 hora del Pacífico para discutir los resultados, accesible por llamada gratuita y a través de webcast en la página de Inversores de la empresa, con una repetición publicada dentro de las 24 horas.
El comunicado reitera declaraciones prospectivas sobre ventas de productos, desarrollo, plazos regulatorios, expansión de la capacidad de fabricación y otros eventos futuros, y señala a los lectores consultar los archivos de la SEC de Amphastar para factores de riesgo y detalles adicionales.
Amphastar Pharmaceuticals (NASDAQ: AMPH)는 2025년 9월 30일로 마감된 2025년 3분기 실적을 2025년 11월 6일 목요일 장 마감 후 발표할 예정이라고 밝혔다. 회사는 그날 오후 미 서부 표준시 2:00에 실적에 대해 토론하는 컨퍼런스 콜을 개최하며, 수신자 부담 전화와 회사 투자자 페이지의 생중계를 통해 접속 가능하며, 24시간 이내에 재방송이 게시된다.
보도자료는 제품 판매, 개발, 규제 시기, 제조 능력 확장 및 기타 향후 이벤트에 대한 미래 지향적 진술을 반복하며 리스크 요인 및 추가 세부 정보는 Amphastar의 SEC 서류를 참조하라고 독자들에게 안내한다.
Amphastar Pharmaceuticals (NASDAQ: AMPH) a déclaré qu'il publiera les résultats de son troisième trimestre 2025, se terminant le 30 septembre 2025, après la clôture du marché le jeudi 6 novembre 2025. La société tiendra une conférence téléphonique ce jour-là à 14h00, heure du Pacifique pour discuter des résultats, accessible par appel gratuit et par webcast sur la page Investisseurs de la société, avec une rediffusion publiée dans les 24 heures.
Le communiqué réitère des déclarations prospectives sur les ventes de produits, le développement, le calendrier réglementaire, l'expansion de la capacité de fabrication et d'autres événements futurs, et invite les lecteurs à consulter les dépôts auprès de la SEC d'Amphastar pour les facteurs de risque et des détails supplémentaires.
Amphastar Pharmaceuticals (NASDAQ: AMPH) hat mitgeteilt, dass die Ergebnisse für das dritte Quartal 2025, das am 30. September 2025 endete, nach Börsenschluss am Donnerstag, dem 6. November 2025 veröffentlicht werden. Das Unternehmen wird an diesem Tag um 14:00 Uhr Pazifischer Zeit eine Konferenzschaltung abhalten, um die Ergebnisse zu besprechen, erreichbar über eine gebührenfreie Rufnummer und über Webcast auf der Investorenseite des Unternehmens, wobei eine Aufzeichnung innerhalb von 24 Stunden veröffentlicht wird.
Die Pressemitteilung wiederholt zukunftsgerichtete Aussagen über Produktverkäufe, Entwicklung, regulatorische Zeitpläne, Erweiterung der Produktionskapazität und andere zukünftige Ereignisse und verweist die Leser auf Amphastars SEC-Einreichungen für Risikofaktoren und zusätzliche Details.
Amphastar Pharmaceuticals (NASDAQ: AMPH) قالت إنها ستصدر نتائج الربع الثالث من عام 2025، الذي انتهى في 30 سبتمبر 2025، بعد إغلاق السوق يوم الخميس 6 نوفمبر 2025. ستعقد الشركة مكالمة مؤتمر في ذلك اليوم الساعة 2:00 مساءً بتوقيت المحيط الهادئ لمناقشة النتائج، يمكن الوصول إليها عبر الاتصال الهاتفي المجاني وبث ويب على صفحة المستثمرين بالشركة، مع نشر إعادة بث خلال 24 ساعة.
يعيد البيان التأكيد على تصريحات مستقبلية حول مبيعات المنتجات والتطوير وتوقيت التنظيم وتوسيع سعة التصنيع وغيرها من الأحداث المستقبلية، ويدعو القراء إلى الرجوع إلى ملفات Amphastar لدى SEC للحصول على عوامل المخاطر وتفاصيل إضافية.
Amphastar Pharmaceuticals (NASDAQ: AMPH) 表示将公布截至2025年9月30日的2025年第三季度业绩，该结果将于 2025年11月6日（星期四） 收盘后发布。公司将于当天 太平洋时间下午2:00 举行电话会议讨论业绩，可通过免费电话拨入及公司投资者页面的网络直播访问，24小时内提供回放。
该新闻稿重申关于产品销售、开发、监管时程、制造产能扩张及其他未来事件的前瞻性陈述，并提醒读者查阅 Amphastar 的 SEC 文件以了解风险因素及其他细节。
- None.
- None.
RANCHO CUCAMONGA, CA / ACCESS Newswire / October 27, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its third quarter of 2025 ended September 30, 2025, after the market closes on Thursday, November 6, 2025, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.
To access the conference call, dial toll-free 877-407-0989, for international calls, dial 201-389-0921, ten minutes before the conference.
The call can also be accessed on the Investors page on the Company's website www.amphastar.com. The webcast replay of the call will be available on our Company website within 24 hours after the end of the live conference call.
Company Information
Amphastar is a bio-pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells insulin API products. Most of the Company's finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. More information and resources are available at www.amphastar.com.
Forward Looking Statements
All statements in this press release and in the conference call referenced above that are not historical are forward-looking statements, including, among other things, statements relating to our expectations regarding future financial performance and business trends, our future growth, sales and marketing of our products, market size and expansion, product portfolio, product development, the timing of FDA filings or approvals, the timing of product launches, acquisitions and other matters related to our pipeline of product candidates, the timing and results of clinical trials, the impact of BAQSIMI® and Primatene MIST®, including their potential for continued revenue growth, the strategic trajectory of and market for our product pipeline, our ability to leverage our existing expertise and technology, expansion of our headquarters, including quadrupling our production capacity and manufacturing capabilities, the resilience of our supply chain, our ability to expand our automation capabilities and integrate advanced technologies, our ability to create new jobs in the future, and other future events. These statements are not facts but rather are based on Amphastar's historical performance and our current expectations, estimates, and projections regarding our business, operations, and other similar or related factors. Words such as "may," "might," "will," "could," "would," "should," "anticipate," "predict," "potential," "continue," "expect," "intend," "plan," "project," "believe," "estimate," and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar's control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar's filings with the Securities and Exchange Commission ("SEC"), including in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 3, 2025, in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 8, 2025, in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, filed with the SEC on August 7, 2025, and our other filings or reports that we may file with the SEC. In particular, there can be no guarantee that our sales strategies will be successful, or that we will continue to experience significant sales of BAQSIMI®. You can locate these reports through our website at http://ir.amphastar.com and on the SEC's website at www.sec.gov. The forward-looking statements in this release speak only as of the date of the release. Amphastar undertakes no obligation to revise or update information or any forward-looking statements in this press release or the conference call referenced above to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause our expectations to change.
Contact:
Bill Peters
Chief Financial Officer
(909) 476-3416
SOURCE: Amphastar Pharmaceuticals, Inc.
View the original press release on ACCESS Newswire
FAQ
When will Amphastar (AMPH) release Q3 2025 earnings and hold the conference call?
How can investors access Amphastar's (AMPH) November 6, 2025 conference call?
Will Amphastar (AMPH) provide a replay of the Q3 2025 earnings call and when?
What period does Amphastar's Q3 2025 earnings release cover for AMPH?
Where can I find risk disclosures and forward-looking statement details for Amphastar (AMPH)?
Who is the Amphastar contact for investor questions about the Q3 2025 release?
